EyePoint prices $200M public offering at $17/share to fund Phase 3 trials for EYP-1901

EyePoint, Inc.

Underwritten public offering of 11,764,706 shares priced at $17.00 per share; underwriters exercised option for additional 1,764,705 shares.
Expected net proceeds ~$215.9M after underwriting discounts and expenses.
Proceeds to fund two pivotal Phase 3 trials of EYP-1901 for wet AMD and other pipeline initiatives.
Closing expected December 8, 2023; J.P. Morgan, TD Cowen, Guggenheim lead underwriters.
Offering upsized from initial $175M to ~$200M gross.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

EyePoint, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, as representative of the underwriters named therein valued at approximately $215.9 million (effective 2023-12-05).

Action: entry
Agreement: underwriting
Counterparty: J.P. Morgan Securities LLC, as representative of the underwriters named therein
Value: approximately $215.9 million
Effective: 2023-12-05

Exact text from the filing

On December 5, 2023, EyePoint Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, as representative of the underwriters named therein (the “Underwriters”), in connection with its previously announced underwritten public offering (the “Offering”) of 11,764,706 shares of the Company’s common stock

View on SEC.gov

Browse all material agreements →

EyePoint, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-290820

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.